目標：探討Statin劑量效應與罹患肝癌之相關性。方法：本篇研究為病例對照研究，利用 國衛院2010年承保抽樣檔納入50歲以上2005-2010年糖尿病之群體（ICD-9 code: 250.x）至少使 用OAD或insulin三個月以上之個案往前回溯Statin暴露量。病例組為糖尿病且被確診肝癌個案 （ICD-9: 155），對照組為糖尿病並未診斷肝癌之個案。結果：HBV（累積劑量>298 DDDs: OR=0.41; 95% CI: 0.24-0.72）或HCV（累積劑量>205 DDDs: OR=0.25; 95% CI: 0.13-0.48）糖 尿病患者若服用Statin累積劑量越高與降低肝癌之風險呈現劑量效應關係（p<0.001）。結論： HBV、HBC之糖尿病個案先前合併使用糖尿病藥物與Statin與降低肝癌之風險呈現劑量效應相 關。（台灣衛誌 2017；36(3)：301-313）

Objectives: To determine the relationship between the dose effect of Statin and the risk of HCC. Methods: This study was a case-control study. All participants were > 50 years of age and were diagnosed with diabetes (ICD-9: 250.x0, 205.x2) and were treated with an antidiabetic agent for at least for 3 months according to the NHID, LHID 2010 (Longitudinal Health Insurance database 2010). We captured the use of a Statin before the index date in patients with type II diabetes. Patients diagnosed with a hepatoma (ICD-9:155) were defined as the case group. Results: The risk of hepatoma was reduced in patients with higher cumulative DDDs Statin use compared to Statin non-users (HBV population: cumulative dose> 298 DDDs [OR=0.41, 95% CI: 0.24-0.72]; HCV population: cumulative dose > 205 DDDs [OR= 0.25; 95% CI: 0.13-0.48]). Conclusions: A dose-response relationship exists between lower risk for hepatoma and higher cumulative DDDs of Statin use. (Taiwan J Public Health. 2017;36(3):301-313)